NASDAQ:AKBA

Akebia Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy AKBA

*Your capital is at risk

$0.97

+0.0333 (+3.56%)

At Close: Jun 03, 2026

Akebia Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 3.10. In total, the insiders bought 10.48M and sold 1.18M AKBA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	3.10
● Buy	10.48M shares
● Sell	1.18M shares
69% Buy Activity Weak Negative Correlation
Sell Signal Low Confidence Feb 02, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 30, 2026 Buy	Common Stock A-Award	Malabre Richard C SVP, Chief Accounting Officer	Officer	79 000 Value: $111.4K
Jan 30, 2026 Buy	Stock Option (Right to buy) A-Award	Malabre Richard C SVP, Chief Accounting Officer	Officer	119 000 Value: $167.8K
Jan 30, 2026 Buy	Common Stock A-Award	Ostrowski Erik SVP, CFO, Cbo & Treasurer	C-Suite Officer	204 000 Value: $287.6K
Jan 30, 2026 Buy	Stock Option (Right to buy) A-Award	Ostrowski Erik SVP, CFO, Cbo & Treasurer	C-Suite Officer	320 000 Value: $451.2K
Jan 30, 2026 Buy	Common Stock A-Award	Butler John P. CEO And President	CEO / President	743 000 Value: $1.05M
Jan 30, 2026 Buy	Stock Option (Right to buy) A-Award	Butler John P. CEO And President	CEO / President	1 115 000 Value: $1.57M
Jan 26, 2026 Buy	Employee Stock Option (right to buy)	Rucci Carolyn M. SVP, Chief Legal Officer	Officer	165 600 Value: $104.3K
Jan 26, 2026 Buy	Employee Stock Option (right to buy)	Rucci Carolyn M. SVP, Chief Legal Officer	Officer	27 900 Value: $60.3K
Jan 26, 2026 Buy	Common Stock	Rucci Carolyn M. SVP, Chief Legal Officer	Officer	0 Value: $0
Jan 26, 2026 Buy	Common Stock	Rucci Carolyn M. SVP, Chief Legal Officer	Officer	0 Value: $0
Jan 26, 2026 Buy	Common Stock	Rucci Carolyn M. SVP, Chief Legal Officer	Officer	0 Value: $0
Jan 26, 2026 Buy	Common Stock	Rucci Carolyn M. SVP, Chief Legal Officer	Officer	0 Value: $0
Jan 26, 2026 Buy	Employee Stock Option (right to buy)	Rucci Carolyn M. SVP, Chief Legal Officer	Officer	61 000 Value: $175.7K
Jan 26, 2026 Buy	Employee Stock Option (right to buy)	Rucci Carolyn M. SVP, Chief Legal Officer	Officer	224 000 Value: $376.3K
Jan 26, 2026 Buy	Employee Stock Option (right to buy)	Rucci Carolyn M. SVP, Chief Legal Officer	Officer	240 000 Value: $537.6K
Jun 30, 2025 Sell	Common Stock S-Sale	Ostrowski Erik SVP, CFO, Cbo & Treasurer	C-Suite Officer	41 314 Value: $151.6K
Jun 30, 2025 Sell	Common Stock S-Sale	Ostrowski Erik SVP, CFO, Cbo & Treasurer	C-Suite Officer	41 314 Value: $151.6K
Jun 10, 2025 Buy	Common Stock A-Award	Zumwalt Leanne M Director	Director	35 700 Value: $139.9K
Jun 10, 2025 Buy	Stock Option (Right to buy) A-Award	Zumwalt Leanne M Director	Director	53 600 Value: $210.1K
Jun 10, 2025 Buy	Common Stock A-Award	Adams Adrian Director	Director	35 700 Value: $139.9K
Jun 10, 2025 Buy	Stock Option (Right to buy) A-Award	Adams Adrian Director	Director	53 600 Value: $210.1K
Jun 10, 2025 Buy	Common Stock A-Award	Wolf Myles Director	Director	35 700 Value: $139.9K
Jun 10, 2025 Buy	Stock Option (Right to buy) A-Award	Wolf Myles Director	Director	53 600 Value: $210.1K
Jun 10, 2025 Buy	Common Stock A-Award	Smith Cynthia Director	Director	35 700 Value: $139.9K
Jun 10, 2025 Buy	Stock Option (Right to buy) A-Award	Smith Cynthia Director	Director	53 600 Value: $210.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AKEBIA THERAPEUTICS

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra...

Read Full Profile Here